Key facts
- It has raised $650K; the latest was Early Stage VC ($2.0M) in Feb 2025.
- Notable investors include TEDCO, Cerdwen, Desire Ventures, HiveBio.
- Status: Privately Held (backing).
Investors
4- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Higher Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Higher Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Higher Medicine
Operator of a healthcare company intended to develop epigenetic therapy. The company aims to usher functional cures for Friedreich's Ataxia (FA) patients with clinically validated p38 MAP kinase inhibitors and other safe small molecules, enabling the healthcare industry to break frontiers as done in Cystic Fibrosis through scientific leaps.
- Sector
- Healthcare
- HQ
- Alexandria, VA, United States
- Founded
- 2024
- Employees
- 5
- Website
- highermedicine.bio/
- Ownership
- Privately Held (backing)
Higher Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Higher Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Higher Medicine in its N-PORT filings yet. We sweep new filings monthly.